Sandia Holdings LLC maintained its position in shares of Cascadian Therapeutics Inc (NASDAQ:CASC) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 543,719 shares of the biopharmaceutical company’s stock at the end of the first quarter. Cascadian Therapeutics makes up about 1.1% of Sandia Holdings LLC’s investment portfolio, making the stock its 21st largest position. Sandia Holdings LLC owned about 1.10% of Cascadian Therapeutics worth $2,251,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Perkins Capital Management Inc. raised its position in Cascadian Therapeutics by 6.4% in the first quarter. Perkins Capital Management Inc. now owns 48,129 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 2,887 shares in the last quarter. Oxford Asset Management raised its position in Cascadian Therapeutics by 32.9% in the first quarter. Oxford Asset Management now owns 162,192 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 40,117 shares in the last quarter. Acadian Asset Management LLC bought a new position in Cascadian Therapeutics during the first quarter valued at about $238,000. Segantii Capital Management Ltd bought a new position in Cascadian Therapeutics during the first quarter valued at about $243,000. Finally, TFS Capital LLC bought a new position in Cascadian Therapeutics during the first quarter valued at about $314,000.
Shares of Cascadian Therapeutics Inc (NASDAQ CASC) traded down 3.45% during mid-day trading on Monday, reaching $3.92. The company had a trading volume of 272,144 shares. The stock has a 50 day moving average of $4.17 and a 200-day moving average of $4.21. The firm’s market capitalization is $193.00 million. Cascadian Therapeutics Inc has a one year low of $3.49 and a one year high of $10.98.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.09. Equities analysts predict that Cascadian Therapeutics Inc will post $5.02 EPS for the current year.
Several research analysts have recently issued reports on CASC shares. Zacks Investment Research upgraded Cascadian Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 7th. Jefferies Group LLC restated a “buy” rating and issued a $10.00 price target (down from $15.00) on shares of Cascadian Therapeutics in a research report on Saturday, March 11th. BTIG Research started coverage on Cascadian Therapeutics in a research report on Friday, April 21st. They issued a “buy” rating on the stock. Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a research report on Tuesday, May 9th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a research report on Wednesday, May 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $6.25.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics Inc (NASDAQ:CASC).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/sandia-holdings-llc-has-2251000-stake-in-cascadian-therapeutics-inc-casc/1882966.html
Receive News & Ratings for Cascadian Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.